The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.

Of 15 treatment-emergent adverse events, only one was deemed related to therapy.

On efficacy, at least, BeOne’s BTK degrader shows an edge.

The company will try to get the Komzifti QTc prolongation warning removed.

Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies. 

Studies presented at ASH show this to be true only up to a point.

Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.